Market Summary
USD164.96+0.87
Market Closed0.53%
ICUI Stock Price
ICUI RSI Chart
ICUI Valuation
ICUI Price/Sales (Trailing)
ICUI Profitability
ICUI Fundamentals
ICUI Revenue
ICUI Earnings
Price Action
52 Week Range
128.90233.88
(Low)(High)
Last 7 days
5.6%
Last 30 days
-2.1%
Last 90 days
4.8%
Trailing 12 Months
-25.9%
ICUI Financial Health
ICUI Investor Care
Peers (Alternatives to ICU Medical)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 108.0B | 18.4B | 9.81% | 7.15% | 45.81 | 5.86 | 7.84% | 18.25% |
ISRG | 89.4B | 6.2B | 12.38% | -15.32% | 67.62 | 14.37 | 8.97% | -22.43% |
BSX | 71.6B | 12.7B | 6.86% | 12.96% | 102.61 | 5.65 | 6.68% | -32.95% |
BDX | 70.1B | 19.0B | 7.04% | -3.24% | 43.54 | 3.69 | -0.43% | -8.78% |
EW | 50.3B | 5.4B | 3.61% | -29.72% | 33.07 | 9.35 | 2.86% | 1.25% |
| MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 14.55% | 4.57% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.6B | 847.1M | 7.86% | 25.46% | -5.3K | 12.54 | 13.32% | -137.89% |
GMED | 5.6B | 1.0B | -2.14% | -23.23% | 32.76 | 5.52 | 6.76% | 24.45% |
IRTC | 3.7B | 410.9M | 4.99% | -21.24% | -32.24 | 9.11 | 27.29% | -14.60% |
TNDM | 2.6B | 801.2M | 10.62% | -65.08% | -27.7 | 3.27 | 14.00% | -707.69% |
| SMALL-CAP | ||||||||
ATEC | 1.7B | 350.9M | 3.38% | 35.65% | -10.93 | 4.74 | 44.26% | -5.42% |
SILK | 1.5B | 138.6M | -18.17% | -5.23% | -27.28 | 10.83 | 36.62% | -10.44% |
AVNS | 1.4B | 820.0M | 5.46% | -11.22% | 27.4 | 1.69 | 10.13% | 701.59% |
CSII | 833.4M | 239.8M | 0.46% | -12.12% | -22.01 | 3.47 | -4.74% | -31.15% |
Financials for ICU Medical
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 11.6% | 2,280 | 2,043 | 1,781 | 1,541 | 1,316 |
| Gross Profit | 7.3% | 698 | 650 | 592 | 548 | 491 |
| Operating Expenses | 10.7% | 741 | 669 | 572 | 493 | 368 |
| S&GA Expenses | 11.2% | 608 | 547 | 468 | 383 | 303 |
| R&D Expenses | 12.4% | 93.00 | 83.00 | 72.00 | 61.00 | 47.00 |
| EBITDA | -65.5% | 45.00 | 130 | 151 | 159 | - |
| EBITDA Margin | -69.1% | 0.02* | 0.06* | 0.08* | 0.10* | - |
| Earnings Before Taxes | -175.6% | -123 | -44.97 | 24.00 | - | - |
| EBT Margin | 10.4% | -0.05* | -0.06* | -0.03* | 0.02* | - |
| Interest Expenses | -226.3% | -66.37 | 53.00 | 32.00 | 15.00 | 2.00 |
| Net Income | -91.3% | -74.29 | -38.83 | 5.00 | 41.00 | 103 |
| Net Income Margin | -71.4% | -0.03* | -0.02* | 0.00* | 0.03* | - |
| Free Cahsflow | -122.2% | -152 | -68.59 | 12.00 | 137 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 1.5% | 4,516 | 4,450 | 4,590 | 4,747 | 1,881 |
| Current Assets | 3.0% | 1,235 | 1,199 | 1,190 | 1,174 | 1,030 |
| Cash Equivalents | -14.4% | 209 | 244 | 256 | 329 | 553 |
| Inventory | 11.3% | 696 | 625 | 583 | 536 | 290 |
| Net PPE | -3.1% | 636 | 656 | 668 | 674 | 468 |
| Goodwill | 5.8% | 1,449 | 1,370 | 1,421 | 1,527 | 43.00 |
| Current Liabilities | 1.1% | 495 | 489 | 486 | 494 | 201 |
| LT Debt, Current | 21.8% | 30.00 | 24.00 | 19.00 | 14.00 | - |
| LT Debt, Non Current | -0.4% | 1,630 | 1,636 | 1,642 | - | - |
| Shareholder's Equity | 3.8% | 2,090 | 2,013 | 2,086 | 2,179 | 1,616 |
| Retained Earnings | -1.8% | 838 | 853 | 866 | 874 | 912 |
| Additional Paid-In Capital | 0.6% | 1,331 | 1,323 | 1,310 | 1,306 | 721 |
| Accumulated Depreciation | - | 437 | - | - | - | - |
| Shares Outstanding | 0.3% | 24.00 | 24.00 | 24.00 | 21.00 | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -379.8% | -62.13 | 22.00 | 99.00 | 215 | 268 |
| Share Based Compensation | -1.8% | 36.00 | 37.00 | 34.00 | 33.00 | 27.00 |
| Cashflow From Investing | 0.5% | -1,909 | -1,918 | -1,926 | -1,939 | -90.69 |
| Cashflow From Financing | 0.3% | 1,637 | 1,632 | 1,631 | 1,635 | -16.87 |
| Buy Backs | 30.6% | 11.00 | 8.00 | - | - | - |
Risks for ICUI
What is the probability of a big loss on ICUI?
68.5%
Probability that ICU Medical stock will be more than 20% underwater in next one year
49.2%
Probability that ICU Medical stock will be more than 30% underwater in next one year.
29.2%
Probability that ICU Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ICUI drawdown profile look like?
Y-axis is the maximum loss one would have experienced if ICU Medical was unfortunately bought at previous high price.
Drawdowns
Returns for ICUI
Cumulative Returns on ICUI
10.9%
10-Year Cumulative Returns
7.0%
7-Year Cumulative Returns
-8.1%
5-Year Cumulative Returns
-6.5%
3-Year Cumulative Returns
What are the long-term rolling returns for ICUI?
FIve years rolling returns for ICU Medical.
Annualized Returns
Which funds bought or sold ICUI recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | reduced | -1.68 | 55,302 | 2,020,780 | 0.02% |
2023-03-17 | American Portfolios Advisors | unchanged | - | -690 | 7,530 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -28.89 | -679,555 | 1,969,440 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -0.96 | 6,000 | 177,000 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -3.14 | 7,424 | 578,424 | -% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | -370 | 630 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 21,000 | 477,000 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -98,000 | - | -% |
2023-02-21 | KB FINANCIAL PARTNERS, LLC | reduced | -20.37 | -1,000 | 7,000 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | added | 11.25 | 2,411,850 | 17,181,800 | 0.03% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
ICU Medical News
Schedule 13G FIlings of ICU Medical
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | t. rowe price investment management, inc. | 10.1% | 2,423,228 | SC 13G/A | |
| Feb 10, 2023 | janus henderson group plc | 10.7% | 2,557,226 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.77% | 2,104,172 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 9.87% | 2,366,386 | SC 13G | |
| Jan 31, 2023 | blackrock inc. | 7.5% | 1,787,807 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 12.8% | 2,725,540 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 9.18% | 1,950,253 | SC 13G/A | |
| Feb 10, 2022 | janus henderson group plc | 10.8% | 2,294,880 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.9% | 1,686,855 | SC 13G/A | |
| Jan 12, 2022 | smiths group international holdings ltd | 10.5% | 2,500,000 | SC 13D |
ICUI Fair Value
ICU Medical fair value in different scenarios
The table shows the Fair Value estimates for ICU Medical for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 95.70 -41.99% | 161.38 -2.17% | 313.85 90.26% | 586.11 255.30% | 985.35 497.33% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical ICU Medical Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of ICU Medical
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 15, 2023 | S-8 | Employee Benefits Plan | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 03, 2023 | S-3ASR | S-3ASR | |
| Feb 27, 2023 | 8-K | Current Report | |
| Feb 27, 2023 | 10-K | Annual Report | |
| Feb 14, 2023 | SC 13G/A | Major Ownership Report |
Latest Insider Trading transactions for ICUI
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-08 | Woolson Daniel | sold (taxes) | -139,616 | 156 | -894 | vp, gm-infusion capital |
2023-03-08 | Bonnell Brian Michael | sold (taxes) | -181,626 | 156 | -1,163 | chief financial officer |
2023-03-08 | Voigtlander Christian B. | acquired | - | - | 2,209 | chief operating officer |
2023-03-08 | Voigtlander Christian B. | sold (taxes) | -181,626 | 156 | -1,163 | chief operating officer |
2023-03-08 | Jain Vivek | sold (taxes) | -207,550 | 156 | -1,329 | chairman and ceo |
2023-03-08 | Woolson Daniel | acquired | - | - | 2,020 | vp, gm-infusion capital |
2023-03-08 | Sanzone Virginia Ruth | sold (taxes) | -186,779 | 156 | -1,196 | vp, general counsel |
2023-03-08 | Sanzone Virginia Ruth | acquired | - | - | 2,272 | vp, general counsel |
2023-03-08 | Jain Vivek | acquired | - | - | 2,525 | chairman and ceo |
2023-03-08 | Bonnell Brian Michael | acquired | - | - | 2,209 | chief financial officer |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
ICUI Income Statement
2022-12-31Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| REVENUES: | |||
| Revenues | $ 2,279,997 | $ 1,316,308 | $ 1,271,004 |
| Cost of Goods Sold | 1,582,236 | 824,818 | 809,507 |
| Gross profit | 697,761 | 491,490 | 461,497 |
| OPERATING EXPENSES: | |||
| Selling, general and administrative | 608,345 | 302,583 | 283,953 |
| Research and development | 92,984 | 47,498 | 42,948 |
| Restructuring, strategic transaction and integration expenses | 71,421 | 18,037 | 28,409 |
| Change in fair value of contingent earn-out | (32,091) | 0 | 9,000 |
| Contractsettlements | 0 | 127 | (975) |
| Total operating expenses | 740,659 | 368,245 | 363,335 |
| Income from operations | (42,898) | 123,245 | 98,162 |
| Interest Income (Expense), Net | (66,375) | 1,982 | 1,924 |
| OTHER INCOME,NET | (5,136) | (2,041) | (2,592) |
| Income before income taxes | (114,409) | 123,186 | 97,494 |
| Provision for income taxes | 40,123 | (20,051) | (10,624) |
| Net Income | $ (74,286) | $ 103,135 | $ 86,870 |
| Basic | $ (3.11) | $ 4.86 | $ 4.16 |
| Diluted | $ (3.11) | $ 4.74 | $ 4.02 |
| WEIGHTED AVERAGE NUMBER OF SHARES | |||
| Basic (in shares) | 23,868 | 21,206 | 20,907 |
| Diluted (in shares) | 23,868 | 21,781 | 21,591 |
ICUI Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $ 208,784 | $ 552,827 |
| Short-term investment securities | 4,224 | 14,420 |
| TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES | 213,008 | 567,247 |
| Accounts receivable, net of allowance for doubtful accounts of $8,530 at December 31, 2022 and $7,038 at December 31, 2021 | 221,719 | 105,894 |
| Inventories | 696,009 | 290,235 |
| Prepaid income taxes | 15,528 | 19,586 |
| Prepaid expenses and other current assets | 88,932 | 46,847 |
| Total current assets | 1,235,196 | 1,029,809 |
| PROPERTY, PLANT AND EQUIPMENT, net | 636,113 | 468,365 |
| Operating Lease, Right-of-Use Assets | 74,864 | 39,847 |
| Long-term Investment Securities | 516 | 4,620 |
| GOODWILL | 1,449,258 | 43,439 |
| INTANGIBLE ASSETS, net | 982,766 | 188,311 |
| Deferred Income Tax Assets, Net | 31,466 | 42,604 |
| Other Assets | 105,462 | 63,743 |
| TOTAL ASSETS | 4,515,641 | 1,880,738 |
| CURRENT LIABILITIES: | ||
| Accounts payable | 215,902 | 81,128 |
| Accrued liabilities | 242,769 | 118,195 |
| Long-Term Debt, Current Maturities | 29,688 | 0 |
| Accrued Income Taxes, Current | 6,200 | 1,454 |
| Total current liabilities | 494,559 | 200,777 |
| Contingent earn-out liability, Noncurrent | 25,572 | 2,589 |
| Long-Term Debt, Noncurrent | 1,623,675 | 0 |
| Other long-term Liabilities | 114,104 | 41,830 |
| Deferred Income Tax Liabilities, Net | 126,007 | 1,490 |
| Accrued Income Taxes, Noncurrent | 41,796 | 18,021 |
| COMMITMENTS AND CONTINGENCIES | 0 | 0 |
| STOCKHOLDERS' EQUITY: | ||
| Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none | 0 | 0 |
| Common stock, $0.10 par value - Authorized-80,000 shares; Issued 23,995 and 21,280 shares at December 31, 2022 and 2021, respectively, and outstanding 23,993 and 21,280 shares at December 31, 2022 and 2021, respectively. | 2,399 | 2,128 |
| Additional paid-in capital | 1,331,249 | 721,412 |
| Treasury Stock, Value | (243) | (27) |
| Retained earnings | 837,501 | 911,787 |
| Accumulated other comprehensive loss | (80,978) | (19,269) |
| Total stockholders' equity | 2,089,928 | 1,616,031 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 4,515,641 | $ 1,880,738 |